Baloxavir marboxil
Based on 13 publication(s) in Google Scholar
Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.96%
- CAS No.: 1985606-14-1
- 화학식: C27H23F2N3O7S
- 분자량:571.55
-
보관:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Pediatric Drug Library
HY-L104
-
Human Metabolite Library
HY-L123
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Baloxavir marboxil
More- Nat Microbiol. 2025 Apr;10(4):836-840. [Abstract]
- Nat Microbiol. 2025 Mar;10(3):784-794. [Abstract]
- Euro Surveill. 2019 Mar;24(12):1900170. [Abstract]
- Emerg Microbes Infect. 2026 Dec;15(1):2601372. [Abstract]
- Int J Mol Sci. 2026 Mar 25;27(7):2967. [Abstract]
- Front Microbiol. 2021 Feb 12:12:611958. [Abstract]
- Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20. [Abstract]
- Influenza Other Respir Viruses. 2025 Oct;19(10):e70176. [Abstract]
- Antiviral Res. 2025 Aug:240:106209. [Abstract]
- ACS Infect Dis. 2025 Oct 30. [Abstract]
- J Virol. 2022 Mar 9;96(5):e0040821. [Abstract]
- Viruses. 2023 Dec 16;15(12):2444. [Abstract]
- bioRxiv. 2025 Sep 22.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
Microbiological Assay
-
Microbiological Assay
Biological Activity
Baloxavir marboxil is a polymerase acidic protein (PA) endonuclease inhibitor[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1985606-14-1
-
Appearance Solid
-
분자량 571.55
-
화학식 C27H23F2N3O7S
-
Color White to yellow
-
SMILES
O=C(C=C1)C(OCOC(OC)=O)=C2N1N([C@H]3C4=CC=C(F)C(F)=C4CSC5=CC=CC=C35)[C@@]6([H])N(CCOC6)C2=O
-
Synonyms
S-033188; RG 6152
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Baloxavir improves disease outcomes in mice after intranasal or ocular infection with Influenza A virus H5N1-contaminated cow's milk. [Abstract]2025 Apr;10(4):836-840. PMID: 40097765 -
Nat Microbiol
2025 Mar;10(3):784-794. PMID: 39929974 -
Euro Surveill
Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. [Abstract]2019 Mar;24(12):1900170. PMID: 30914078 -
Emerg Microbes Infect
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses from humans in the United States, October 2024 to February 2025. [Abstract]2026 Dec;15(1):2601372. PMID: 41392919
Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2026 Dec;15(1):2601372. [Abstract]
Effect of Baloxavir marboxil (5-45 mg/kg; oral gavage; Twice daily for 5 days.) treatment in mice inoculated with A(H5N1) virus with or without PA-I38M. Female six-week-old BALB/c mice (n = 16/group) were inoculated with 5× MLD50 of A/California/147/2024 (CA/147, wildtype) (A,C,E,G) or A/California/150/2024 (CA/150, PA-I38M mutation) (B, D, F, H). Immediately after infection (∼2hpi), all inoculated mice we treated twice daily by oral gavage with Baloxavir marboxil or placebo for 5 days (purple horizontal bar). Survival (A, B) and body weights (C, D) were monitored daily for 14 (CA/147, A and C) or 21 (CA/150, B and D) days (n = 8 mice per treatment dose).
-
Int J Mol Sci
Baloxavir Acid-Induced Mitochondrial Toxicity and Cell Cycle Arrest Contribute to Its Adverse Effects. [Abstract]2026 Mar 25;27(7):2967. PMID: 41977157 -
Front Microbiol
Improved in vitro Efficacy of Baloxavir Marboxil Against Influenza A Virus Infection by Combination Treatment With the MEK Inhibitor ATR-002. [Abstract]2021 Feb 12:12:611958. PMID: 33679636
Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2021 Feb 12:12:611958. [Abstract]
Antiviral activity of Baloxavir marboxil (BXA) or ATR-002 against both recombinant wild type and BXA-resistant influenza virus strains. rgA/Giessen/06/2009 (H1N1), rgA/Victoria/3/75 (H3N2). Confluent monolayer of MDCK-II cells were infected with the respective virus strains (MOI = 0.001) and incubated for 1 h. Subsequently, cells were treated by adding infection media containing either BXA (0.9 nM) or ATR-002 at the indicated concentrations. After 24 h, the virus titers were determined by focus assay.
-
Antimicrob Agents Chemother
Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. [Abstract]2020 Jun 23;64(7):e00222-20. PMID: 32312780 -
Influenza Other Respir Viruses
Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies. [Abstract]2025 Oct;19(10):e70176. PMID: 41116245
Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Influenza Other Respir Viruses. 2025 Oct;19(10):e70176. [Abstract]
Five days of treatment, commencing at 1 dpi, body weight changes, and a 14-day survival rate in each group (n = 6). The survival rates in each treatment group were compared with the placebo group. he results showed that when the treatment time was extended to 5 days post-infection, both Baloxavir marboxil (BXM, 15 mg/kg; p.o.; twice daily) and combination treatments improved body weight and survival. The combination group also showed the highest survival rate.
Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Influenza Other Respir Viruses. 2025 Oct;19(10):e70176. [Abstract]
Effects of the molnupiravir and Baloxavir marboxil (BXM, 15 mg/kg; p.o.; twice daily) combination treatment on the pathological changes following influenza H1N1 infection. Lung tissue harvested at 4 dpi was stained with H&E. The images on the left showed the pathological changes in each group (n = 6), with a scale bar of 2 mm. The images in the middle and right (a-h) were magnified from the corresponding squares on the left, with a scale bar of 100 μm. Histological results indicated that lung damage and inflammation in the BXM and combination groups were less severe than those in the other groups (p < 0.05).
-
Antiviral Res
High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay. [Abstract]2025 Aug:240:106209. PMID: 40484321
Baloxavir marboxil purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2025 Aug:240:106209. [Abstract]
Inhibitory concentration 50 (IC50) expressed in nM of reference compounds (A) included in retesting experiments, (B) interval obtained through multiple determinations. Note: Inhibitory concentration 50 (IC50) interval of VX-787, ribavirin and oseltamivir have been obtained through multiple determinations for A/WSN/33 and A/Udorn/72. Baloxavir marboxil IC50 range for A/WSN/33 and A/Udorn/72 comes from 5 independent determinations. A/Ca/07/09 data for VX-787, Baloxavir marboxil, oseltamivir and ribavirin come from 3 independent determinations.
-
ACS Infect Dis
Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]2025 Oct 30. PMID: 41166549 -
J Virol
Identification of Amino Acid Residues Required for Inhibition of Host Gene Expression by Influenza Virus A/Viet Nam/1203/2004 H5N1 PA-X. [Abstract]2022 Mar 9;96(5):e0040821. PMID: 33853954 -
Viruses
2023 Dec 16;15(12):2444. PMID: 38140686 -
용액&용해도
DMSO : 33.33 mg/mL (58.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 25 mg/mL (43.74 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Frederick G Hayden, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923. [Content Brief]
[2]. Hideyuki Ikematsu, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med. 2020 Jul 23;383(4):309-320. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7496 mL | 8.7481 mL | 17.4963 mL | 43.7407 mL |
| 5 mM | 0.3499 mL | 1.7496 mL | 3.4993 mL | 8.7481 mL | |
| 10 mM | 0.1750 mL | 0.8748 mL | 1.7496 mL | 4.3741 mL | |
| 15 mM | 0.1166 mL | 0.5832 mL | 1.1664 mL | 2.9160 mL | |
| 20 mM | 0.0875 mL | 0.4374 mL | 0.8748 mL | 2.1870 mL | |
| 25 mM | 0.0700 mL | 0.3499 mL | 0.6999 mL | 1.7496 mL | |
| 30 mM | 0.0583 mL | 0.2916 mL | 0.5832 mL | 1.4580 mL | |
| 40 mM | 0.0437 mL | 0.2187 mL | 0.4374 mL | 1.0935 mL | |
| 50 mM | 0.0350 mL | 0.1750 mL | 0.3499 mL | 0.8748 mL |
Powered by Bioz